Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental combo targets tough blood cancers

NCT ID NCT05986240

First seen Nov 11, 2025 · Last updated May 23, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug called danvatirsen, first alone and then combined with venetoclax, in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to standard treatments. The goal is to see if the treatment is safe and can shrink or control the cancer. About 38 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M.D. Anderson Cancer Center, Department of Leukemia

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.